获得性 BCL2 变异与急性髓系白血病中的维奈托克耐药相关。
Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia.
发表日期：2024 Oct 07
作者：
Fiona C Brown, Xin Wang, Richard W Birkinshaw, Chong Chyn Chua, Thomas David Morley, Sila Kasapgil, Giovanna Pomilio, Piers Blombery, David Ching Siang Huang, Peter E Czabotar, Salvatore F Priore, Guang Yang, Martin P Carroll, Andrew H Wei, Alexander E Perl
来源：
Blood Advances
摘要：
我们报告并描述了急性髓系白血病 (AML) 的维奈托克/阿扎胞苷治疗期间出现的三种对维奈托克耐药的 BCL2 变异。我们的结果表明 AML 患者复发时可能出现靶向维奈托克耐药性。版权所有 © 2024 美国血液学会。
We report and characterize three venetoclax-resistant BCL2 variants arising during venetoclax/azacitidine therapy in acute myeloid leukemia (AML). Our results indicate the potential for on-target venetoclax resistance in patients with AML at relapse.Copyright © 2024 American Society of Hematology.